| Bosulif (bosutinib) / Pfizer |
2021-006581-20: A patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia |
|
|
| Not yet recruiting | 4 | 106 | Europe | Tablet, Capsule, hard, Imatinib, SPRYCEL, Bosulif, Tasigna, Iclusig | Radboud univeristy medical centre, ZonMw | Chronic myeloid leukaemia, Blood cancers, leukaemia, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Recruiting | 4 | 347 | Europe, Canada, Japan, US, RoW | Asciminib single agent, ABL001, Imatinib, STI571, Nilotinib, AMN107, Bosutinib, Dasatinib, Sprycel | Novartis Pharmaceuticals | Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 08/30 | 08/30 | | |
| Active, not recruiting | 3 | 233 | Europe, Canada, Japan, US, RoW | Asciminib, ABL001, Bosutinib | Novartis Pharmaceuticals | Chronic Myelogenous Leukemia | 05/20 | 12/24 | | |
|
2021-000678-27: A study to compare oral asciminib versus existing TKI medicines in patients with newly diagnosed CML Vizsgálat az orálisan alkalmazott asciminib és tirozin-kináz inhibitor (TKI) között újonnan diagnosztizált krónikus mieloid leukémiában (CML) szenvedő betegeknél |
|
|
| Ongoing | 3 | 402 | Europe | Asciminib, Bosulif, Glivec, Tasigna, Sprycel, ABL001, STI571, AMN107, Film-coated tablet, Capsule, hard, Bosulif, Glivec, Tasigna, Sprycel | Novartis Pharma AG, Novartis Farmacéutica S.A., Novartis Pharma AG | Chronic Myelogenous Leukemia in chronic phase (CML-CP) in newly diagnosed patients, CML is a bone marrow cancer caused by a gene mutation which causes over growth of white blood cells., Diseases [C] - Cancer [C04] | | | | |
2022-004165-20: Discontinuation of Tyrosine Kinase Inhibitors in chronic myeloid leukemia and impact on the immune system: a randomized controlled trial of two therapeutic strategies |
|
|
| Not yet recruiting | 3 | 140 | Europe | IMATINIB, DASATINIB, Tasigna, BOSULIF, Tablet, Capsule, IMATINIB, DASATINIB, NILOTINIB, BOSUTINIB | CHU de Poitiers, CHU de Poitiers, GIRCI SOHO | chronic myeloid leukemia, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Imatinib, STI571, Nilotinib, AMN107, Bosutinib, Dasatinib, Asciminib, ABL001 | Novartis Pharmaceuticals, Novartis Pharma AG | Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | 11/23 | 01/28 | | |
| Recruiting | 3 | 285 | US | olverembatinib, Bosutinib | Ascentage Pharma Group Inc. | Chronic Myeloid Leukemia, CML, CML, Chronic Phase | 12/25 | 02/26 | | |
2016-002216-40: Efficacy, safety and tolerability of a drug called Bosutinib, in eldery patients affected by Chronic Myeloid Leukemia failing front-line treatment with other drugs with similar features. Studio sull'efficacia, sicurezza e tollerabilit¿ di un farmaco denominato Bosutinib in pazienti anziani affetti da Leucemia Mieloide Cronica non responsivi a trattamenti di elezione con altri farmaci con caratteristiche simili. |
|
|
| Not yet recruiting | 2 | 65 | Europe | Tablet, BOSULIF - 100 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/ACLAR/PVC) - 30 COMPRESSE | FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, Pfizer, A.I.L Associazione Italiana contro le Leucemie | Chronic Myeloid Leukemia (CML) in Chronic Phase Leucemia Mieloide Cronica (LMC) in Fase Cronica, Chronic Myeloid Leukemia (CML) is a type of cancer starts in certain blood-forming cells of the bone marrow. In CML a genetic change takes place in a early (immature) version of myeloid cells- the cel La leucemia mieloide cronica (LMC) ¿ una forma di cancro che ha origine dalle cellule del midollo osseo che rappresentano i precursori delle cellule del sangue (piastrine, globuli rossi e globuli bian, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2018-001843-29: Trial to investigate if the addition of novel agents in combination with TKI can improve response compared to TKI alone in patients with TKI resistant chronic myeloid leukaemia. |
|
|
| Not yet recruiting | 2 | 102 | Europe | Imatinib, Nilotinib, Dasatinib, Bosutinib, Ponatinib, Tazemetostat, EPZ-6438, Film-coated tablet, Capsule, hard | NHS Greater Glasgow and Clyde, University of Glasgow, , Cancer Research UK, Epizyme | Chronic myeloid leukaemia, Chronic myeloid leukaemia, Diseases [C] - Cancer [C04] | | | | |
2018-001044-54: A study of effect and safety of a new combination of drugs for chronic myeloid leukemia in chronic phase. Bosutinib is the basis treatment and patients will be randomized to receive or not to receive a long-acting low dose of Ropeginterferon. Satunnaistettu, etenevä KML:n ensilinjan lääkehoitotutkimus: Lääkeaineen tehoa ja turvallisuutta mittaava tutkimus, jossa pieniannoksinen ropeginterferoni lisätään bosutinibihoitoon hiljattain diagnosoitua, kroonisessa vaiheessa olevaa kroonista myelooista meukemiaa sairastavilla potilailla. |
|
|
| Not yet recruiting | 2 | 212 | Europe | Pegylated proline-interferon alpha 2b, AOP2014, Tablet, Solution for injection in pre-filled pen, Bosulif | St Olavs Hospital -Trondheim University Hospital, Pfizer Norge AS, AOP Orphan Pharmaceuticals AG | Chronic myeloid leukemia at diagnosis-chronich phase Diagnoosivaiheen krooninen myelooinen leukemia, kroonisessa vaiheessa, Chronic myeloid leukemia, a type of blood cancer Krooninen myelooinen leukemia, verisyöpätyyppi, Diseases [C] - Cancer [C04] | | | | |
BOGI, UMIN000032282: A phase 2 study of Bosutinib Gradual Increase as a second or third line treatment for chronic myeloid leukemia in chronic phase |
|
|
| Enrolling by invitation | 2 | 35 | Japan | Bosulif (bosutinib) - Pfizer | Saga University, Pfizer; Akita University | Chronic myeloid leukemia | | | | |
TOKIN, NCT04626024: Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population |
|
|
| Recruiting | 2 | 100 | US | Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal, Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation, Gleevec, Sprycel, Tasigna, Bosulif | Baylor College of Medicine | Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission | 11/25 | 11/25 | | |
S1712, NCT03654768: Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia |
|
|
| Active, not recruiting | 2 | 84 | US | Bosutinib, Bosulif, SKI 606, SKI-606, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Laboratory Biomarker Analysis, Nilotinib, AMN107, NILOTINIB HYDROCHLORIDE MONOHYDRATE, Nilotinib Monohydrochloride Monohydrate, Tasigna, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Imatinib, Gleevec®, STI-571 | SWOG Cancer Research Network, National Cancer Institute (NCI) | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | 07/24 | 07/28 | | |
BosuPeg, NCT03831776: Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis |
|
|
| Recruiting | 2 | 212 | Europe | Bosutinib, Ropeginterferon, RoPegIFN | St. Olavs Hospital, Haukeland University Hospital, Oslo University Hospital, University Hospital of North Norway, Helse Stavanger HF, Henri Mondor University Hospital, Hôpital René Huguenin, Hôpital Mignot, Versailles Paris, Uppsala University Hospital, Odense University Hospital | Chronic Myeloid Leukemia | 02/24 | 03/28 | | |
| Not yet recruiting | 2 | 50 | Europe | Ponatinib 15mg QD, ICLUSIG, AP24534, Ponatinib 30mg QD | Associazione Italiana Pazienti Leucemia Mieloide Cronica | Chronic Myeloid Leukemia (CML) | 10/24 | 04/25 | | |
READIT, NCT04578847: A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) |
|
|
| Active, not recruiting | 2 | 100 | RoW | Imatinib, Nilotinib, Dasatinib, Bosutinib | National Research Center for Hematology, Russia | Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission, BCR-ABL Positive Chronic Myelogenous Leukemia | 01/25 | 01/25 | | |
| Recruiting | 2 | 720 | Canada | Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib, Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Erlotinib, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib, Tucatinib | Canadian Cancer Trials Group, AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Seagen Inc. | Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors | 01/26 | 01/27 | | |
| Active, not recruiting | 1/2 | 60 | US | Bosutinib | Children's Oncology Group, Erasmus Medical Center, Dutch Childhood Oncology Group, Innovative Therapies for Children with Cancer, Pfizer | Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia | 07/28 | 07/28 | | |
NCT04793399: Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients |
|
|
| Terminated | 1/2 | 9 | Europe | Bosutinib 400 MG Monotherapy, Bosulif, Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection, Bosulif + Tecentriq | Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica, Pfizer, Roche Farma, S.A | Chronic Phase-Chronic Myeloid Leukemia | 09/21 | 09/21 | | |
NCT04744532: iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study |
|
|
| Recruiting | 1/2 | 49 | Japan | Bosutinib (Phase 1 part), PF-05208763, Bosutinib (Phase 2 part) | Kyoto University, Tokushima University, Kitasato University, Tottori University, Nara Medical University, Toho University, Hiroshima University, Pfizer | Amyotrophic Lateral Sclerosis | 03/24 | 03/24 | | |
NCT03854903: WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor |
|
|
| Active, not recruiting | 1 | 19 | US | Palbociclib, Ibrance, Bosutinib, Bosulif, Fulvestrant, Faslodex | Georgetown University, Pfizer | Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer | 11/23 | 11/25 | | |
NCT02921477: Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias |
|
|
| Enrolling by invitation | 1 | 150 | US | bosutinib, bosulif, TKI | Neurological Associates of West Los Angeles, Pfizer | Mild Cognitive Impairment, Dementia | 12/23 | 12/25 | | |
NCT05743465: A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia |
|
|
| Completed | N/A | 1769 | US | No Intervention | Takeda | Leukemia | 11/22 | 11/22 | | |
| Completed | N/A | 702 | Japan | Bosutinib, BOSULIF | Pfizer | Chronic Myelogenous Leukemia | 02/24 | 02/24 | | |
NCT06297161: A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML). |
|
|
| Not yet recruiting | N/A | 600 | NA | Bosulif | Pfizer | Chronic Leukemia Myelogenous | 12/29 | 12/29 | | |
NCT05682924: Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib |
|
|
| Recruiting | N/A | 105 | RoW | taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry | Samara State Medical University | Chronic Myeloid Leukaemia | 05/23 | 05/23 | | |